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Background: The detection of molecular and cytogenetic alterations is important for the diagnosis,
prognosis and classification of myeloproliferative neoplasms.
Objectives: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon 12
and MPL W515K/L, besides chromosomal abnormalities. Furthermore, molecular and cytogenetic
alterations were correlated with the leukocyte and platelet counts, hemoglobin levels and age in all
patients and with the degree of fibrosis in primary myelofibrosis cases.
Methods: Twenty cases of polycythemia vera, 17 of essential thrombocythemia and 21 of primary
myelofibrosis were selected in the Hematology Department of the Universidade Federal de São Paulo
(UNIFESP) between February 2008 and December 2009. The JAK2 V617F, JAK2 exon 12 mutations,
MPL W515K and MPL W515L mutations were investigated by real-time PCR and direct sequencing.
G-band karyotyping and fluorescence in situ hybridization were used to detect chromosomal
abnormalities.
Results: Chromosomal abnormalities were observed only in polycythemia vera (11.8%) and primary
myelofibrosis cases (17.6%), without correlation to clinical data. Chromosomal abnormalities were
not detected by fluorescence in situ hybridization. The JAK2 V617F mutation was observed in
polycythemia vera (90%), primary myelofibrosis (42.8%) and essential thrombocythemia (47%).
Patients with JAK2 V617F-negative polycythemia vera had lower platelet and leukocyte counts compared
to V617F-positive polycythemia vera (p-value = 0.0001 and p-value = 0.023, respectively). JAK2
V617F-positive and MPL W515L-positive primary myelofibrosis cases had a higher degree of fibrosis
than V617F-negative cases (p-value = 0.022). JAK2 exon 12 mutations were not detected in polycythemia
vera patients. The MPL W515L mutation was observed in one case of primary myelofibrosis and in
one of essential thrombocythemia. The MPL W515K mutation was not found in patients with essential
thrombocythemia or primary myelofibrosis. The MPL W515L-positive patient with primary
myelofibrosis had more severe anemia than other patients with primary myelofibrosis.
Conclusions: This study demonstrates that karyotyping for JAK2 and MPL mutations is useful in the
diagnosis of myeloproliferative neoplasms. The precise pathogenetic contribution of these alterations
is still unclear. However, this study adds more information about the pathophysiology of polycythemia
vera, essential thrombocythemia and primary myelofibrosis.
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Introduction
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis
(PMF) are clonal hematopoietic stem cell disorders and constitute a heterogeneous group
of diseases characterized by increased proliferation and maturation of the erythroid,
megakaryocytic or myeloid lineages.(1)
In recent years there has been renewed interest in the molecular characterization and
classification of myeloproliferative neoplasms (MPN) and the targeted therapy. This interest
began with the discovery of the JAK2 V617F mutation in BCR-ABL1-negative patients.
However, the exact role of JAK2 mutations remains unknown, therefore it is not known yet
whether the JAK2 V617F mutation is the first event in MPN or is secondary to other
genetic and epigenetic events.(2)
The JAK2 and MPL genes play important roles in cell signaling and proliferation.(3)
Mutations in these genes confer constitutive activation of the JAK-STAT pathway and
other pathways promoting differentiation and proliferation of different lineages.(4) The JAK2
V617F mutation is present in approximately 95% of patients with PV, 58% with PMF and
50% with ET.(1) The MPL W515L mutation is present in about 9% of patients with PMF and
5% with ET.(5) Another mutation, MPL W515K, is present in 5% of patients with PMF and
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1% with ET.(6) MPL mutations are not described in PV or
other myeloid diseases to date.(6) In JAK2 V617F-negative
PV cases, some mutations have been described in exon 12
of the JAK2 gene, corresponding to approximately 3% of
all PV cases. These mutations have not been described in
PMF and ET.(7)
PV, PMF and ET have common clinical and biological
aspects that hinder their diagnosis and thus cytogenetic and
molecular studies are important tools to clarify the
pathophysiological and clinical features in these diseases.
Thus, the investigation of the JAK2 V617F, MPL W515K
and MPL W515L mutations and of cytogenetic alterations
using karyotyping and fluorescence in situ hybridization
(FISH) may provide a more detailed understanding of the
pathophysiology processes of PV, PMF and ET, as well as
being important in the diagnosis, prognosis and classification
of these diseases.(8)
Methods
Patients and samples
Twenty patients diagnosed with PV, 21 with PMF and
17 with ET according to World Health Organization (WHO)
criteria (2008) were selected in the Hematology Department
of the Universidade Federal de São Paulo (UNIFESP) between
February 2008 and December 2009. G-band karyotyping and
FISH were used to evaluate bone marrow samples (3 mL),
while peripheral blood samples (3 mL) were collected to
investigate the JAK2 V617F, MPL W515K and MPL W515L
mutations. The age, gender, leukocyte count, platelet count,
hemoglobin concentration, degree of marrow fibrosis and
duration of disease were noted from the patients' records.
Patients with unclear diagnoses or that did not agree to
participate in the study were excluded. The study was
approved by the Research Ethics Committee of UNIFESP.
G-band karyotyping
Briefly, 3 mL of bone marrow harvested in sodium
heparin was cultivated for a short time without mitogens.
Then, 70 uL of Colcemid® were added and after 30 minutes
the sample was centrifuged and the supernatant discharged.
Potassium chloride (0.075 mol/L) was added to the pellet for
20 minutes followed by fixing using Carnoy`s fixative three
times.(9) Part of the sample (1 mL) was allocated for FISH and
stored in a refrigerator at 4°C until use. Some material was
dripped on glass slides, air dried, aged and banded using
trypsin-Giensa (GTG). Chromosomal abnormalities were
described according to the International System for Human
Cytogenetic Nomenclature (ISCN - 2009).(10) The definition
of a clone, from the cytogenetic point of view, was the
presence of the same structural anomaly in at least two cells
or the absence of the same chromosome in at least three
metaphases.(9)
Fluorescence in Situ Hybridization (FISH)
The following probes were used for FISH according to
the manufacturer's instructions: centromere of chromosome
8 (Alpha satellite 8 Green, CytoCell Aquarius probe),
centromere of chromosome 9 (Classical satellite 9 red, Cytocell
Aquarius probe), region 13q14.3 and 13qter (13q14.3 deletion
probe, Cytocell Aquarius probe) and region 20q12 and 20q13.1
(del 20q, Cytocell Aquarius probe). These probes recognize
the regions of the most common chromosomal alterations
reported in MPN.
After informed consent, samples from three bone
marrow donors were used as normal controls. These values
were defined using the β-inverse function in Microsoft Excel
software.(11) All cases were investigated by two observers,
each of whom examined 100 cells, and the mean was calculated
for each observer. The number of cells analyzed was increased
to 500 when there was a discrepancy of more than 10%
between the means or when the end result was very close to
the cutoff point. When more than 20% of cells showed no
signal, the slide was considered not analyzable and the test
was repeated.
Investigation of the JAK2 V617F, MPL W515K
and MPL W515L mutations
An investigation of the JAK2 V617F mutation was
performed for all 58 patients and the MPL W515K and
MPL W515L mutations for all 21 PMF and 17 ET patients by
real-time PCR. Genomic DNA was extracted from peripheral
blood collected in EDTA using the QiAmp® DNA Blood
Mini kit (Qiagen).
PCR was performed using the JAK2 MutaScreenTM kit
(Ipsogen) and the MPL MutaScreenTM kit (Ipsogen), which
contains a positive control (100% mutated alleles), negative
control (0% mutated alleles), reference sample (2% of mutated
alleles) and a mixture of primers and probes. For each reaction
the following reagents were used: 12.5 uL of Taqman Universal
PCR Master Mix (Applied Biosystems), 2.5 uL of the mixture
of primers and probes and 25 ng of DNA giving a final volume
of 25 uL. The reaction conditions (50°C for two minutes,
followed by 95°C for 10 minutes, 50 cycles of 92°C for 15
seconds and 60°C for one minute) were according to the
instructions of the manufacturer for the JAK2 MutaScreenTM
kit (Ipsogen). A Rotor-GeneTM 3000 (Corbert) thermal cycler
was used.
Investigation of mutations in exon 12 of the
JAK2 gene
All PV patients were selected to analyze exon 12 of
the JAK2 gene by direct sequencing. A preliminary
amplification of exon 12 was performed using PCR. For the
PCR reaction the following reagents were used: 5 mL buffer
amplifier (10x), 3 mL of MgCl2 (25 mmol/L), 2 mL of dNTP
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(containing 2.5 mM of each nucleotide), 1 unit Taq polymerase
(Fermentas, USA), 2 mL of each primer (10 mM) and 100 ng of
DNA in a final volume of 50 µL. The primers used for the
amplification of exon 12 have the following sequences:
5'-CATACTTTCAGTGTATTTTGAAGTG-3' (forward) and
5'-ATGTCACATGAATGTAAATCAAG-3' (reverse). The
reaction conditions were 94°C for 5 minutes, 40 cycles of
94°C for 30 seconds, 59°C for 30 seconds and 72°C for 45
seconds, with a final extension of 72°C for 7 minutes. After
PCR, the amplification was checked by 1% agarose gel
electrophoresis stained with ethidium bromide. After
amplification of the fragments of interest by PCR, samples
were purified with the QIAquick PCR Purification kit (Qiagen)
according to the manufacturer's information. Direct
sequencing of purified PCR products was performed for both
strands, using the dideoxy chain-termination method
(BigDyeTM Terminator v.3.0 Ready Reaction Cycle
Sequencing Kit - Applied Biosystems). The resulting
sequences were compared to those described in the GenBank
and Ensembl reference sequence databases (http://
www.ncbi.nlm.nih.gov/sites/entrez and http://www.
ensembl.org) using the CLC Sequence Viewer program (http://
www.clcbio.com/index.php?id=28) and BioEdit (http://
www.mbio.ncsu.edu/BioEdit/bioedit.html).
Statistical analysis
The Statistical Package for the Social Sciences (SPSS®)
version 18 was used for statistical analysis. The Shapiro-
Wilk test was used to assess normal distribution of
continuous variables. Student's t test was used to analyze
variables with normal distribution and the Mann-Whitney
test for non-normal distribution. The chi-square associated
with Yates correction was used to compare degrees of fibrosis
between groups with and without specific mutations (JAK2
V617F and MPL W515K / L) and between groups for disease
diagnosis or monitoring. The level of significance in the tests
was set for an alpha error of 5% (p-value < 0.05).
Results
G-band Karyotyping
Chromosome abnormalities were detected in 2/17
(11.8%) patients with PV, 3/17 (17.6%) with PMF and no
cases with ET. The alterations identified in PV were
del(13)(q14) and loss of the Y chromosome and in PMF
trisomy 8 (two cases) and one case of trisomy 9 were
detected (Table 1).
FISH
No cases presented abnormalities for the regions
analyzed (13q14.3, 13qter, 20q12, 20q13.1 and centromeres of
chromosome 8 and 9) as shown in Table 1. Figure 1 shows
normal results of FISH probes for the 13q14.3 and 13qter
regions.
Investigation of JAK2 V617F and MPL W515K/L
The JAK2 V617F mutation was detected in 18/20 (90%)
cases of PV, 9/21 (42.9%) of PMF and 8/17 (47.1%) of ET.
Investigations of the MPL W515K and MPL W515L were
performed for all patients with ET and PMF. The MPL W515L
mutation was found in 1/21 (4.8%) cases of PMF and 1/17
(5.9%) of ET. The MPL W515K mutation was not detected
(Table 1). Figure 2 shows the curves drawn by the analysis
program showing a JAK2 V617F-positive patient.
Investigation of mutations in exon 12 of the JAK2 gene
No patients with PV, even the two cases who did not
have the JAK2 V617F mutation, exhibited mutations in exon
12 of the JAK2 gene (Table 1). Figure 3 shows an
electropherogram from the BioEdit program; there are no
anomalous peaks compared with the sequence pattern and
thus no differences in the sample tested.
Number of clonal events analyzed
There were no PV patients with concomitant mutations
in exon 12 of the JAK2 gene and the JAK2 V617F mutation.
Likewise, no PMF and ET patients had JAK2 V617F together
with MPL W515L or MPL W515K mutations. However, one
patient with PV and two with PMF had the JAK2 V617F
mutation and abnormal karyotypes (Table 1).
Correlation with clinical data
Of the 20 patients with PV, 12 (60%) were male and 8
(40%) were female with a mean age of 60.4 ± 11.9 years old.
Of the 21 patients with PMF, 11 (52.3%) were male and 10
(47.7%) were female with an average age of 64.9 ± 13.5 years
old. And of the 17 patients with ET, four (23.5%) were male
and 13 (76.5%) were female with an average age of 59.3 ± 14.5
years old. There were no statistical differences between the
mean ages of patients with different diseases (p-value = 0.60).
No correlation was found in respect to: age, the leukocyte
count, platelet count, hemoglobin concentrations, and
molecular cytogenetic alterations between the different groups
of patients. However, PV patients without the JAK2 V617F
mutation presented lower leukocyte and platelet counts
compared to JAK2 V617F-positive PV patients. The average
platelet counts of JAK2 V617F-negative and -positive PV
patients were 202.5 x 109/L and 683.3 x 109/L, respectively
(p-value < 0.0001), and the mean leukocyte counts of
JAK2 V617F-negative and -positive PV patients were 8.8
x109/L and 13 x109/L, respectively (p-value = 0.023 - Table 2).
The PMF patient with the MPL W515L mutation was
older (87 years) than the average age of the JAK2 V617F-
positive and -negative PMF patients (59.2 and 67.7,
respectively). In addition, her hemoglobin level (6.4 g/dL) was
lower than the mean of JAK2 V617F-positive and -negative
PMF patients (12.03 g/dL and 11.53 g/dL, respectively). The
mean hemoglobin for all patients with PMF was 11.5 g/dL, the
mean leukocyte count was 15.8 x109/L and the mean platelet
count was 628 x 109/L.
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Figure 1 – Metaphase showing signals for the 13q14.3 region in red
and for 13qter in green, i.e., there is no loss or gain of chromosomal
material in these regions
Figure 2 – JAK2 V617F-positive patient
1: positive control (100% of mutated alleles); 2: Sample tested;
3: Reference sample (2% of mutated alleles); 4: Negative control (0%
of mutated alleles)
Figure 3 – Electropherogram of the BioEdit program, showing the absence of mutations in exon 12 of the JAK2 gene
For polycythemia vera and primary myelofibrosis, the
data on age, platelet count and hemoglobin levels are
expressed as means and the leukocyte count as a median.
For essential thrombocythemia, the data on leukocyte and
platelet counts and hemoglobin levels are expressed as
medians and the age as a mean.
There was a significant difference between the degree
of fibrosis and presence of the JAK2 V617F and MPL W515L
mutations in PMF cases (p-value = 0.022). Patients with
positive markers (JAK2 V617F and MPL W515L) had a higher
degree, usually grade III, of fibrosis (Figure 4). The patient
with MPL W515L also presented with a stage of sclerosing
fibrosis. There was no statistical difference between the
degree of fibrosis and the duration of the disease, i.e., patients
Figure 4 – Relationship between the degree of fibrosis and the presence
of molecular markers (JAK2 V617F and MPL W515L) in primary
myelofibrosis patients (p-value = 0.022)
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with the disease longer did not have a more intense degree of
fibrosis (p-value = 1).
Discussion
Chromosomal abnormalities are observed at diagnosis
in between 10 to 25% of patients with PV,(12) about 30% with
PMF(13) and 7% with ET.(14) Thus the incidence of
chromosomal abnormalities found here was a little lower for
PV and PMF than what has been reported in the literature,
i.e., 11.8% of patients with PV and 17.6% with PMF. In some
cases it was not possible to obtain a satisfactory mitotic
index (20 metaphases). Due to fibrosis in PMF cases, it is
common to have an insufficient number of metaphases and
there is no way to overcome this difficulty in karyotyping.
Therefore FISH is useful in these cases. However, FISH did
not help in detecting chromosomal alterations in this study.
In addition, patients on myelosuppressive agents may have
low mitotic indexes. The alternative would be the suspension
of the drug before sample collection; an option not considered
due to the clinical consequences.
The del(13q) abnormality is present in 10% of cases
of PMF and PV and in rare cases of ET.(12,14,15) Furthermore,
this deletion is not related to changes in the clinical course
of the disease.(13) Here, the patient with del(13q) showed no
discrepancy regarding the mean leukocyte and platelet
counts and hemoglobin levels compared to other patients
with PV.
Trisomy 8 is present in about 20% of cases of PV, 6% of
PMF and 10% of ET.(12,14) The prognosis conferred by the
presence of trisomy 8 is not yet fully defined. One of the
cases studied here presented a complicated clinical course,
with thrombotic events leading to death, while the other had
a clinical outcome similar to patients with normal karyotypes
and no history of thrombotic events.
Trisomy 9 is present in 10% of PMF, PV and ET
cases.(12,14) The prognosis of patients with this alteration is
controversial in terms of survival and evolution of the disease,
but more recent studies have shown that this abnormality is
a sign of worse prognosis in PMF.(13,15) The patient with
trisomy 9 did not show discrepancies in the mean leukocyte
and platelet counts and hemoglobin levels compared to the
other PMF patients.
The loss of the Y chromosome is present in 4% of
PV patients and is associated with older age but has no
prognostic relevance.(12) The patient in this case was a
60-year-old man who did not have the JAK2 V617F
mutation.
The use of more sensitive techniques could extend the
threshold of abnormalities detected; the thresholds for G-
band karyotyping, FISH and array comparative genomic
hybridization (CGH-a) are 5 Mb, 1 Mb and 50 Kb,
respectively.(16) CGH-a has the potential to detect
submicroscopic genomic imbalances and may be carried out
with DNA without the need of metaphases and is a surrogate
for cases of bone marrow fibrosis.(17) In 2009, Tefferi et al.
showed that CGH-a expands the detection of chromosomal
abnormalities in PMF patients.(17) However, the discovery of
numerous genomic imbalances by CGH-a has no clinical
significance yet; no conclusion has been reached regarding
prognosis, therapeutic response and evolution of PMF related
to such micro-alterations.
The incidence of the JAK2 V617F mutation observed
in this study (90% of cases of PV, 42.8% of PMF and 47% of
ET) is similar to reported data. The incidence of the mutation
can vary somewhat between studies and it is believed that
one of the factors responsible for these differences is the
sensitivity of the method used.(18-21)
Although the vast majority of PV patients present the
JAK2 V617F mutation, about 5% were V617F negative, even
when using more sensitive detection methods. These cases
require further investigations of other mutations, such as
mutations in exon 12 of the JAK2 gene which also
characterize gain of function. However, we did not identify
PV patients with mutations in exon 12, suggesting that there
may be other, as yet unknown, mutations. In this study, two
PV cases did not have mutations in exon 12 or the JAK2
V617F mutation. The diagnoses of these two cases were
confirmed by the WHO criteria (2008). Both had hemoglobin
levels ≥ 18.5 g/dL as a major criterion, and low serum
erythropoietin levels and hypercellular bone marrow biopsies
with prominent erythroid, granulocytic and megakaryocytic
proliferations as minor criteria. One of these patients had a
clonal alteration, loss of the Y chromosome, while no
abnormality was detected for the other. In respect to clinical
data, these two patients had lower platelet and leukocyte
counts (p-value < 0.0001 and p-value = 0.023, respectively)
compared to JAK2 V617F-positive PV patients. These data
show that the absence of JAK2 mutations may improve the
excessive proliferation of megakaryocytic and granulocytic
series in PV cases.
The sensitivity of the method used also influences
the detection of mutations in exon 12 of the JAK2 gene.
Recent studies show that such mutations are present in a
small fraction of granulocytes of some patients. In addition,
several groups have demonstrated that conventional
Sanger sequencing without enrichment of the sample, as
used in this study, cannot detect this type of
mutation.(7,22,23) Laughlin et al. presented a technique called
clamp that favors the amplification of the mutant allele,
thereby increasing the analytical capabilities of testing.(24)
The use of even more advanced technology, coupled with
the enrichment of the sample, are significant improvements
in the detection of most or all of the mutations in exon 12
of the JAK2 gene.
The relationship between survival, clinical course,
transformation of the disease and JAK2 V617F is not yet
fully defined. In addition, the literature does not provide
reports of significant associations of V617F, MPL mutations
and degree of fibrosis in patients with PMF. Here we
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demonstrated a statistical difference between patients with
these molecular markers (JAK2 V617F and MPL W515L)
and fibrosis (p-value = 0.003). Most V617F-positive patients
had Grade III fibrosis, whereas most V617F-negative
individuals had Grade II fibrosis. The fact that no statistical
correlation was found between the duration of the
disease and increases in the degree of fibrosis in this
study (p-value = 1) reinforces the idea that the presence of
molecular markers (JAK2 V617F and MPL W515L) promote
greater complications in these patients. The increase in the
degree of bone marrow fibrosis may promote pancytopenia
(due to ineffective hematopoiesis), extramedullary
hematopoiesis (spleen), production of atypical cells
(atypical megakaryocytes and tear cells) and a greater
likelihood of transformation to acute leukemia.
The incidence of the MPL W515L mutation was similar
to the literature. MPL W515K mutations were not found.
Cases of ET and PMF with MPL mutations have similar
morphological and pathological bone marrow results as cases
of ET and PMF with JAK2 mutations, including
hypercellularity and fibrosis.
ET patients with MPL mutations show no statistically
significant differences in relation to platelet levels when
compared to JAK2 V617F-positive ET patients. However, a
statistical difference is detected when hemoglobin levels are
compared. Thus, ET patients with MPL mutations have lower
hemoglobin levels when compared to JAK2 V617F-positive
ET patients.(25) The ET patient with MPL W515L had a platelet
count similar to the mean count as JAK2 V617F-positive ET
cases (748 x 109/L and 858 x 109/L, respectively), a slightly
lower leukocyte count (14.8 x109/L and 18.2 x 109/L, respectively)
and almost the same level of hemoglobin (13.5 g/dL and
13.7 g/dL, respectively).
The PMF patient with the MPL W515L mutation
presented a different clinical course from the JAK2 V617F-
positive PMF patients. She was an 87-year old and had
severe anemia (hemoglobin 6 g/dL) that was more
pronounced than in JAK2 V617F-positive and -negative
patients. In addition, she had Grade III fibrosis, highlighting
that the MPL W515L mutation is more aggressive compared
to the JAK2 V617F mutation. The patient died due to
abdominal thrombosis.
Thus, the results of this study show that karyotyping
and analysis of JAK2 V617F and MPL W515L mutations are
useful tools in the diagnosis of MNP, making it more precise.
The presence of JAK2 and MPL mutations demonstrates
different clonal alterations, indicating the presence of different
pathophysiological mechanisms in these diseases.
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